Teva-Kowa To Commence Marketing Generics In Japan In January
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Teva-Kowa Pharma, a ¥360 million 50-50 joint venture of Teva - the world's largest generics manufacturer - and Japan's diversified manufacturer group Kowa, Dec. 16 said it would commence marketing generic drugs in Japan beginning in January, a few months ahead of schedule
You may also be interested in...
Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
Daiichi Sankyo Goes After Generics In Japan, Forms New Company With Ranbaxy
MUMBAI - As Teva and Mylan drill deeper into the steadily unfolding Japanese generic drugs market, Daiichi Sankyo - the third largest Japanese drug maker - does not want to be left behind
Teva-Kowa Accelerates Japanese Generic Expansion With Taisho Acquisition
Teva-Kowa Pharma announced Dec. 24 it will purchase a majority stake in mid-size generic competitor Taisho Pharmaceutical Industries. The acquisition gives the joint venture immediate access to 220 generic products and 50 sales staff